Newswise — New Haven, Conn. — Yale Cancer Center (YCC) is pleased to announce the appointments of Thomas Prebet, M.D., Ph.D., as Disease Aligned Research Team (DART) Leader for Myeloid Malignancies and Amer Zeidan, MBBS, as Director of the Hematology Early Therapeutics Program. In these new roles, Prebet and Zeidan will work closely with Stephanie Halene, M.D., Ph.D., Interim Chief of Hematology at YCC.
Prebet is an Associate Professor of Medicine (Hematology) and is focused on developing clinical trials for myeloid malignancies and translational advances for patients with acute myeloid leukemia and myelodysplastic syndromes. In his new role as DART leader for myeloid malignancies, he will oversee the clinical trial team for myeloid malignancies and work to develop a complete portfolio of trials for our patients.
Zeidan is an Associate Professor of Medicine (Hematology) and is the Yale principal investigator for multiple NCI-sponsored and clinical trials in myeloid malignancies. Zeidan is also chairing the steering committee for a large pharma-sponsored randomized trial of myelodysplastic syndromes (MDS). As Director of the Hematology Early Therapeutics Program, Zeidan will partner closely with Patricia LoRusso, D.O., Associate Cancer Center Director for Experimental Therapeutics at YCC, to develop a comprehensive Phase I clinical trial portfolio for patients with hematologic malignancies.
Prebet and Zeidan start their new roles immediately.
About Yale Cancer Center and Smilow Cancer Hospital Yale Cancer Center (YCC) is one of only 51 National Cancer Institute (NCI-designated comprehensive cancer) centers in the nation and the only such center in Connecticut. Cancer treatment for patients is available at Smilow Cancer Hospital through 13 multidisciplinary teams and at 15 Smilow Cancer Hospital Care Centers in Connecticut and Rhode Island. Smilow Cancer Hospital is accredited by the Commission on Cancer, a Quality program of the American College of Surgeons. Comprehensive cancer centers play a vital role in the advancement of the NCI’s goal of reducing morbidity and mortality from cancer through scientific research, cancer prevention, and innovative cancer treatment.